Business Wire

Samsung SDI Launches Battery Brand PRiMX

Share

On the 29th, Samsung SDI (KRX:006400) announced that it has launched its battery brand PRiMX (Pronounced as Praimax). Samsung SDI is to promote the super-gap technology strategy through the launch of the brand that conveys the company’s identity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211228005221/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung SDI launched its battery brand PRiMX that conveys Samsung SDI’s unique identity. PRiMX stands for ‘Prime Battery for Maximum Experience.’ The brand was developed under the three keywords, ‘Absolute Quality,’ ‘Outstanding Performance,’ and ‘Proven Advantage.’ For PRiMX, trademark registration has been completed not only in Korea but also in Europe and is soon to be registered in the U.S. Samsung SDI will apply PRiMX to all batteries it produces to achieve high quality and technology befitting the three keywords. (Graphic: Business Wire)

PRiMX stands for ‘Prime Battery for Maximum Experience.’ The brand was developed under the three keywords, ‘Absolute Quality,’ ‘Outstanding Performance,’ and ‘Proven Advantage.’

'Absolute Quality', the first keyword, means the safest and most reliable battery quality. Samsung SDI has strengthened quality control for the whole process from battery development to manufacturing and shipping. It conducts a strict quality inspection such as selecting materials and design that can improve battery quality at the development phase, advancing the defect detection algorithm with the deep learning-based AI test at the manufacturing and shipping phase, and examining about 500 quality items throughout the entire manufacturing process.

‘Outstanding Performance’ means a high-capacity and high-power battery technology with Samsung SDI’s latest materials technology including high nickel cathode and silicon anode, and its unrivaled manufacturing capability. It is crucial to determine key performances, such as electric vehicle mileage and output of power tools.

‘Proven Advantage’ means user convenience achieved with the company’s independently developed technology. In particular, the super-fast charging technology developed using a new technique is said to be a groundbreaking technology to minimize the lithium-ion transport distance and time by reducing resistance inside the battery cell.

For PRiMX, trademark registration has been completed not only in Korea but also in Europe and is soon to be registered in the U.S. Samsung SDI will apply PRiMX to all batteries it produces to achieve high quality and technology befitting the three keywords.

With the launch of PRiMX, Samsung SDI opened a microsite and released a brand introduction video. The video helps viewers easily understand the meaning and characteristics of PRiMX.

“PRiMX is a battery brand that conveys Samsung SDI’s unique identity,” said Executive Vice President Michael Son of Samsung SDI Strategic Marketing Team. “We will develop the brand to reach the pinnacle of technology.”

For more information on Samsung SDI and PRiMX, visit www.samsungsdi.com and https://sdi-on.com/primx/en/ (microsite).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samsung SDI
Dongjun Choi
+82-2-2255-2616
d-jun.choi@samsung.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

IonQ Unanimously Appoints Peter Chapman as Next Chairman of the Board of Directors26.4.2024 13:30:00 CEST | Press release

IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today the appointment of Peter Chapman as its next Chairman of the Board and Harry You as the Lead Independent Director of the Board, effective at the close of IonQ’s upcoming Annual General Meeting on June 5, 2024. Both appointments were disclosed in a proxy statement issued on April 25, 2024. Peter Chapman has also been nominated for re-election as a Class III director at the meeting, and his chairmanship will take effect assuming he is re-elected. “Last quarter we were delighted to have appointed Robert Cardillo and Bill Scannell to our Board of Directors. In addition, the Board unanimously appointed Peter Chapman to serve as its next Chairman following the annual meeting given his half-decade worth of contributions to IonQ and his strong progress transitioning IonQ from an academic to a commercial company,” said Niccolo de Masi, Chairman of the Nominating & Corporate Governance Committee of IonQ’s Board. “Unde

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye